清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial

医学 彭布罗利珠单抗 肉瘤 软组织肉瘤 骨肉瘤 内科学 临床终点 外科 队列 癌症 软组织 肿瘤科 临床试验 病理 免疫疗法
作者
Hussein A. Tawbi,Melissa Burgess,Vanessa Bolejack,Brian A. Van Tine,Scott M. Schuetze,James Hu,Sandra P. D’Angelo,Steven Attia,Richard F. Riedel,Dennis A. Priebat,Sujana Movva,Lara E. Davis,Scott H. Okuno,Damon R. Reed,John Crowley,Lisa H. Butterfield,Ruth Salazar,Jaime Rodriguez‐Canales,Alexander J. Lazar,Ignacio I. Wistuba,Laurence H. Baker,Robert G. Maki,Denise K. Reinke,Shreyaskumar Patel
出处
期刊:Lancet Oncology [Elsevier]
卷期号:18 (11): 1493-1501 被引量:1109
标识
DOI:10.1016/s1470-2045(17)30624-1
摘要

Background Patients with advanced sarcomas have a poor prognosis and few treatment options that improve overall survival. Chemotherapy and targeted therapies offer short-lived disease control. We assessed pembrolizumab, an anti-PD-1 antibody, for safety and activity in patients with advanced soft-tissue sarcoma or bone sarcoma. Methods In this two-cohort, single-arm, open-label, phase 2 study, we enrolled patients with soft-tissue sarcoma or bone sarcoma from 12 academic centres in the USA that were members of the Sarcoma Alliance for Research through Collaboration (SARC). Patients with soft-tissue sarcoma had to be aged 18 years or older to enrol; patients with bone sarcoma could enrol if they were aged 12 years or older. Patients had histological evidence of metastatic or surgically unresectable locally advanced sarcoma, had received up to three previous lines of systemic anticancer therapy, had at least one measurable lesion according to the Response Evaluation Criteria In Solid Tumors version 1.1, and had at least one lesion accessible for biopsy. All patients were treated with 200 mg intravenous pembrolizumab every 3 weeks. The primary endpoint was investigator-assessed objective response. Patients who received at least one dose of pembrolizumab were included in the safety analysis and patients who progressed or reached at least one scan assessment were included in the activity analysis. Accrual is ongoing in some disease cohorts. This trial is registered with ClinicalTrials.gov, number NCT02301039. Findings Between March 13, 2015, and Feb 18, 2016, we enrolled 86 patients, 84 of whom received pembrolizumab (42 in each disease cohort) and 80 of whom were evaluable for response (40 in each disease cohort). Median follow-up was 17·8 months (IQR 12·3–19·3). Seven (18%) of 40 patients with soft-tissue sarcoma had an objective response, including four (40%) of ten patients with undifferentiated pleomorphic sarcoma, two (20%) of ten patients with liposarcoma, and one (10%) of ten patients with synovial sarcoma. No patients with leiomyosarcoma (n=10) had an objective response. Two (5%) of 40 patients with bone sarcoma had an objective response, including one (5%) of 22 patients with osteosarcoma and one (20%) of five patients with chondrosarcoma. None of the 13 patients with Ewing's sarcoma had an objective response. The most frequent grade 3 or worse adverse events were anaemia (six [14%]), decreased lymphocyte count (five [12%]), prolonged activated partial thromboplastin time (four [10%]), and decreased platelet count (three [7%]) in the bone sarcoma group, and anaemia, decreased lymphocyte count, and prolonged activated partial thromboplastin time in the soft-tissue sarcoma group (three [7%] each). Nine (11%) patients (five [12%] in the bone sarcoma group and four [10%] in the soft-tissue sarcoma group) had treatment-emergent serious adverse events (SAEs), five of whom had immune-related SAEs, including two with adrenal insufficiency, two with pneumonitis, and one with nephritis. Interpretation The primary endpoint of overall response was not met for either cohort. However, pembrolizumab showed encouraging activity in patients with undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma. Enrolment to expanded cohorts of those subtypes is ongoing to confirm and characterise the activity of pembrolizumab. Funding Merck, SARC, Sarcoma Foundation of America, QuadW Foundation, Pittsburgh Cure Sarcoma, and Ewan McGregor.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Mistletoe完成签到 ,获得积分10
8秒前
creep2020完成签到,获得积分10
25秒前
li8888lili8888完成签到 ,获得积分10
54秒前
1分钟前
AJ完成签到 ,获得积分10
1分钟前
dreamwalk完成签到 ,获得积分10
1分钟前
sunny完成签到,获得积分10
1分钟前
xuli21315完成签到 ,获得积分10
2分钟前
科研螺丝完成签到 ,获得积分10
2分钟前
缺粥完成签到 ,获得积分10
2分钟前
凶狠的盛男完成签到 ,获得积分10
2分钟前
2分钟前
狐狸小姐完成签到 ,获得积分10
3分钟前
zhangguo完成签到 ,获得积分10
3分钟前
知行者完成签到 ,获得积分10
3分钟前
LOST完成签到 ,获得积分10
3分钟前
3分钟前
稻子完成签到 ,获得积分10
3分钟前
zhangsan完成签到,获得积分10
3分钟前
3分钟前
小皮猪发布了新的文献求助10
4分钟前
小旺啦完成签到 ,获得积分10
4分钟前
杳鸢应助小皮猪采纳,获得20
4分钟前
4分钟前
小强完成签到 ,获得积分10
5分钟前
jimmy_bytheway完成签到,获得积分0
5分钟前
5分钟前
Ava应助guan采纳,获得10
5分钟前
巫巫巫巫巫完成签到 ,获得积分10
6分钟前
长情半邪完成签到 ,获得积分10
6分钟前
6分钟前
summer完成签到,获得积分10
6分钟前
韩寒完成签到 ,获得积分10
6分钟前
6分钟前
小西完成签到 ,获得积分10
6分钟前
poki完成签到 ,获得积分10
7分钟前
Serein完成签到,获得积分10
7分钟前
无悔完成签到 ,获得积分10
7分钟前
7分钟前
wx1完成签到 ,获得积分0
8分钟前
高分求助中
Licensing Deals in Pharmaceuticals 2019-2024 3000
Effect of reactor temperature on FCC yield 2000
Very-high-order BVD Schemes Using β-variable THINC Method 1020
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 800
Mission to Mao: Us Intelligence and the Chinese Communists in World War II 600
MATLAB在传热学例题中的应用 500
Geochemistry, 2nd Edition 地球化学经典教科书第二版,不要epub版本 431
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3303305
求助须知:如何正确求助?哪些是违规求助? 2937611
关于积分的说明 8482651
捐赠科研通 2611539
什么是DOI,文献DOI怎么找? 1425981
科研通“疑难数据库(出版商)”最低求助积分说明 662524
邀请新用户注册赠送积分活动 647005